KOSDAQBiotech & Pharma039860

NanoenTek

₩3,765▼ 2.71%2026-11-18 close
Market Cap
₩143.4B
Turnover
₩700M
Volume
170K
Shares out.
38.1M
PER
99.4×
PBR
1.7×
EPS
₩42
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Sales Growth Meets a Q3 2026 Operating Loss

Annual operating profit rose to KRW 1.1 billion in 2025, but the third quarter of 2026 returned to an operating loss of KRW 226 million and a controlling-shareholder net loss of KRW 3.85 billion, making the direction of quarterly profit the key item to monitor.

  1. 1

    Revenue reached KRW 38.1 billion in 2025, up 25.2% from the prior year, and operating profit rose 77.4% to KRW 1.1 billion.

  2. 2

    Third-quarter 2026 revenue fell 16.2% from the previous quarter to KRW 10.5 billion, and the company posted an operating loss of KRW 226 million and a controlling-shareholder net loss of KRW 3.85 billion.

  3. 3

    The company said FREND product sales rose 77% to KRW 12.1 billion in 2025, and the United States accounted for the largest share of sales at 57.9% in the first half of 2025.

  4. 4

    Net income is strongly affected by foreign-exchange gains and losses, as both the 2025 decline and the surge in the first quarter of 2026 were attributed to currency effects.

  5. 5

    Equity was KRW 91 billion and total liabilities were KRW 7.03 billion at the end of 2025, so debt is small, but the small earnings base makes earnings-based multiples sensitive to quarterly results.

02

Business structure

NanoEnTek runs two segments, in vitro diagnostics and life sciences, built on microfluidic lab-on-a-chip technology. Its flagship in vitro diagnostics products are the FREND point-of-care immunoassay system and the ADAM series of automated cell counters.

The life sciences segment supplies cell analysis and counting instruments and laboratory consumables used across CAR-T and other cell therapy development, manufacturing and quality control.

In the first half of 2025, product mix was 68.6% in vitro diagnostics consumables, 18.6% life sciences consumables, 4.4% life sciences instruments, 2.6% in vitro diagnostics instruments, 2.1% merchandise and 3.7% other, so consumables totaled 87.2%.

Regional mix over the same period was 57.9% United States, 21.9% Europe, 7.3% Korea and 12.9% other, meaning exports exceeded 90% of sales. The company said FREND product sales rose 77% to KRW 12.1 billion in 2025.

On October 1, 2025, it made AAI Healthcare a wholly owned subsidiary to extend into AI-based digital health services, and AAI Healthcare reported sales of KRW 2.0 billion in the first quarter of 2026. In Germany, it acquired the distributor Med-Tech Supplies GmbH to build direct sales in Europe.

Key customers include Samsung Biologics, Johnson & Johnson and AstraZeneca. The largest shareholder, a Korean asset advisory firm, held 20.0%, and including related parties the stake was 41.1% as of the first half of 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.6B-₩65,059,131−0.8%
2025Q4₩12.6B₩900M7.2%
2026Q1₩10.5B₩100M1.4%
2026Q2₩12.5B₩700M5.5%
2026Q3₩10.5B-₩200M−2.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩35.2B₩4.4B₩4.7B12.4%8.1%9.8%
2023₩26.8B-₩2.2B-₩3.7B−8.3%−6.9%9.3%
2024₩30.5B₩600M₩3.6B2.0%4.8%6.8%
2025₩38.1B₩1.1B₩1.6B2.9%1.7%7.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue fell from KRW 35.2 billion in 2022 to KRW 26.8 billion in 2023, a decline of 23.8%, before rising to KRW 30.5 billion in 2024 (up 13.5%) and KRW 38.1 billion in 2025 (up 25.2%), marking two consecutive years of growth from 2024 through 2025.

In 2023, operating income turned to an operating loss of KRW 2.23 billion, and controlling-shareholder net income turned to a net loss of KRW 3.68 billion. In 2024, operating profit returned to KRW 621 million and controlling-shareholder net income was KRW 3.59 billion.

In 2025, operating profit rose 77.4% to KRW 1.1 billion, while controlling-shareholder net income fell 55.9% to KRW 1.58 billion. The company attributed the net income decline to lower foreign-exchange-related gains as currency volatility eased.

The operating margin went from 12.4% in 2022 to -8.3% in 2023, then 2.0% in 2024 and 2.9% in 2025, still well below the 2022 level.

The company cited higher U.S. male hormone diagnostic supply and the AAI Healthcare consolidation as drivers of 2025 profit growth, while U.S. tariffs and heavier marketing at the U.S. and German subsidiaries raised costs.

Operating cash flow went from KRW -646 million in 2023 and KRW -602 million in 2024 to KRW 4.15 billion in 2025. Quarterly results show an operating loss of KRW 65.06 million in the third quarter of 2025, followed by operating profit of KRW 909 million in the fourth quarter, a turn to profit.

In the first quarter of 2026, revenue was KRW 10.5 billion (down 17.0% from the previous quarter), with operating profit of KRW 149 million and controlling-shareholder net income of KRW 1.45 billion.

In the second quarter, revenue rose to KRW 12.5 billion (up 19.2% quarter on quarter) and operating profit to KRW 687 million.

In the third quarter of 2026, revenue was KRW 10.5 billion (down 16.2% from the prior quarter, up 22.5% year on year), with an operating loss of KRW 226 million, and a controlling-shareholder net loss of KRW 3.85 billion that was much larger than the operating loss, suggesting non-operating items had a large effect.

Controlling-shareholder net income over the latest four quarters totaled KRW 1.37 billion, and with swings this large quarter to quarter, full-year trends alone do not show the earnings base clearly.

05

Industry analysis

The company attributes FREND sales growth to continued demand for male hormone diagnostics in the United States. U.S.-bound sales in 2024 were KRW 17.4 billion, up 26.6%, and the company said U.S. subsidiary sales surpassed domestic sales for the first time that year.

In female hormone diagnostics, the company expects its market to expand as U.S. regulation eases on female hormone therapy. In cell therapy, the EVE-HT A26 automated cell analysis robot and the Cell Bioprint developed with L'Oréal target demand from pharmaceutical companies and research institutes.

In its first-quarter 2026 results release, the company said it was in supply discussions with Kite Pharma (a Gilead company), Umoja Biopharma and the UCSF Cell Design Institute. The company said it will focus on CDMO firms that require large-scale production.

In Europe, the company said its German subsidiary's sales roughly quadrupled in 2024 as it adapted to demanding local requirements. The company stresses that large pharma companies weigh warranty and customer support alongside product performance.

Market share versus competitors is hard to gauge with external figures beyond the company's own description of a leading position in U.S. male hormone diagnostics, so its market standing should be read alongside its sales trend.

On tariffs, U.S. duties were a cost headwind in 2025, and the company said unit price increases would offset tariff effects in 2026.

06

Outlook

For 2026, the company pointed to three growth drivers: the first supply of the EVE-HT A26 automated cell analysis robot, field testing of the Cell Bioprint, and expanded U.S. supply of male and female hormone diagnostic products.

The company said in March 2026 that it was discussing delivery schedules and terms for EVE-HT A26 with five global pharmaceutical companies and cell therapy research institutes.

Cell Bioprint units are shipping to nine countries for field testing, and the company expects supply to begin in the second quarter and volumes to expand in the second half.

The company said a women's health diagnostic product is set to launch in the second half, and its sales contribution after launch is an item to track in periodic filings. AAI Healthcare is expanding into digital health services that combine AI with remote medicine, and the company expected further growth from it.

The company expected growth to continue in the second quarter, and revenue did rise to KRW 12.5 billion. In the third quarter, however, revenue was KRW 10.5 billion with an operating loss of KRW 226 million.

The company said unit price increases and lower marketing costs would improve profitability in 2026, and whether this shows up in full-year profitability can be checked in the 2026 annual report.

The next checkpoints are the second-half supply volume of the Cell Bioprint and the sales contribution of the women's health diagnostic product after its launch.

07

Valuation

PER
99.4×
PBR
1.7×
ROE
1.7%
EPS
₩42
BPS
₩2,479
Dividend per share
₩0

Market capitalization is above total equity of KRW 91 billion at the end of 2025, which places the stock in a range where it carries a premium to book value.

Earnings-based multiples are sensitive to quarterly results because the earnings base is small, and controlling-shareholder net income over the latest four quarters totaled KRW 1.37 billion.

The company moved from profit in 2022 to a loss in 2023 and back to profit in 2024 and 2025, but the profitable stretch is short, so the longer earnings track record is limited. The dividend yield is effectively close to zero, which places the company further from a dividend-based income profile.

Compared with listed peers in biopharma, NanoEnTek's business centers on diagnostic instruments and cell analysis equipment, so a like-for-like comparison is difficult. After the third-quarter 2026 operating loss, the reference point for interpreting multiples is full-year earnings in the 2026 annual report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Rising U.S. diagnostic product sales

The company said FREND product sales rose 77% to KRW 12.1 billion in 2025. The company attributes this to continued U.S. demand for male hormone diagnostics and a broader female hormone diagnostic lineup. U.S. subsidiary sales reached KRW 17.4 billion in 2024, up 26.6%, surpassing domestic sales for the first time. The company expects supply volumes to grow again in 2026.

AAI Healthcare consolidation and digital health expansion

AAI Healthcare became a wholly owned subsidiary on October 1, 2025, and the company reported first-quarter 2026 sales of KRW 2.0 billion. The company describes the unit as expanding into digital health services that combine AI with remote medicine.

The consolidation was also cited as a factor in 2025 annual profit improvement. How the subsidiary's results separate from the diagnostics and life sciences segments is an item to follow in the periodic filings' segment information.

Cell therapy equipment talks and a second-quarter profit

The company said in March 2026 that it was discussing delivery terms for EVE-HT A26 with five global pharmaceutical companies and cell therapy research institutes. Cell Bioprint units are shipping for field testing to nine countries, including the United States, France, the United Kingdom, Korea, China and Japan.

Second-quarter 2026 revenue rose 19.2% quarter on quarter to KRW 12.5 billion, with operating profit of KRW 687 million.

09

Bear factors

Return to losses in the third quarter of 2026

Third-quarter 2026 revenue was KRW 10.5 billion, down 16.2% from the previous quarter, and the operating loss was KRW 226 million. The operating loss widened from a year-earlier loss. Controlling-shareholder net income moved from KRW 633 million a year earlier to a net loss of KRW 3.85 billion.

Earnings swings from currency gains and losses

Controlling-shareholder net income fell 55.9% to KRW 1.58 billion in 2025, which the company attributed to lower foreign-exchange-related gains. The company also said the surge in first-quarter 2026 net income reflected foreign currency translation gains from a rising exchange rate.

Operating results and net income can move in different directions, and whether this gap recurs is the next item to check.

Concentration in overseas sales and tariff costs

In the first half of 2025, the United States accounted for 57.9% of sales and Europe for 21.9%, so exports exceeded 90%. U.S. tariffs were included among the 2025 cost headwinds described in the disclosure.

The company said unit price increases would offset tariff effects in 2026, but exposure to trade-policy changes remains.

10

Risk factors

Trade and tariff risk

With high U.S. and European sales shares, tariff policy and local regulatory changes directly affect the revenue mix. Tariffs raised costs in 2025, and the company said it would respond with unit price increases in 2026.

The actual effect of those increases is an item to check in revenue and profit trends in the 2026 annual report.

Currency and foreign-exchange volatility

Net income depends heavily on currency translation and foreign-exchange gains and losses, which can open a gap with operating results. The 2025 decline and the first-quarter 2026 surge in net income were both explained by exchange rates. With a small earnings base, a single currency move can flip the sign of net profit.

Timing of new businesses and ownership concentration

Supply talks for the EVE-HT A26 and the Cell Bioprint have not yet been specified with contract sizes and delivery dates in filings, so timing could slip. The largest shareholder and related parties held 41.1% as of the first half of 2025, which may leave a relatively narrow free float.

11

What to watch next

  1. By late December 2026

    Confirm whether the women's health diagnostic product planned for the second half has launched, and which items were included. A launch would support the expansion of the female hormone diagnostic lineup.

  2. Disclosure-driven, from December 2026 onward

    Check whether EVE-HT A26 delivery contracts and Cell Bioprint supply volumes are specified in filings or reports. Disclosed contract sizes would allow a rough estimate of the cell therapy equipment share of sales.

  3. By the end of March 2027

    This is the 2026 annual report deadline and the first point to check full-year 2026 sales, operating profit, operating cash flow and fourth-quarter results. The key question is whether the operating margin holds above the 2.9% recorded in 2025.

  4. Around mid-May 2027 (estimate)

    This is the expected timing for the first-quarter 2027 results, estimated from the 2026 first-quarter release date. Check whether the third-quarter 2026 losses continue and how much AAI Healthcare contributes to sales.

12

Overall view

NanoEnTek grew both sales and operating profit in 2025, with revenue of KRW 38.1 billion and operating profit of KRW 1.1 billion, and FREND products and the AAI Healthcare consolidation were the core growth drivers.

However, third-quarter 2026 revenue declined from the prior quarter and the company posted an operating loss of KRW 226 million and a controlling-shareholder net loss of KRW 3.85 billion, so the stability of quarterly profit is still to be confirmed.

Bullish factors are the expanding supply of U.S.-focused diagnostic products, supply talks for cell therapy equipment, and the second-quarter 2026 operating profit of KRW 687 million.

Bearish factors are the third-quarter loss, net income swings from currency effects, and concentration in overseas sales with tariff exposure. Net income is heavily influenced by foreign-currency items and can move differently from operating profit.

On valuation, the small earnings base means multiples respond strongly to changes in results. The next checkpoints are the launch of the women's health diagnostic product in the second half of 2026, Cell Bioprint supply volumes, and the operating margin in the 2026 annual report. This report is for information only and includes no investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. newsis.com
  2. digitaltoday.co.kr
  3. v.daum.net
  4. v.daum.net
  5. hankyung.com
  6. news.nate.com
  7. mdtoday.co.kr
  8. v.daum.net
  9. m.newsprime.co.kr
  10. doctorstimes.com
  11. kr.investing.com
  12. finance-scope.com
  13. kr.investing.com
  14. hellot.net
  15. investing.com
  16. news.nate.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis